<DOC>
	<DOCNO>NCT00603148</DOCNO>
	<brief_summary>This study begin define critical determinant patient undergoing procedure hybrid interventional cardiology/cardiac surgery suite . In future study , data obtain study use prospectively stratify patient term bleed verse thrombotic risk design study optimize anticoagulation anti-platelet therapy hybrid setting .</brief_summary>
	<brief_title>The Role Platelet Surface α2β1 Integrin Expression Risk Factor Thrombotic and/or Bleeding Complications</brief_title>
	<detailed_description>The aim study test association DNA polymorphism link level αβ1 integrin expression platelet clinical outcome term bleed thrombotic complication . The association polymorphism gene GPVI , PAR-1 , COX-2 , well PLA ½ status , also examine consider context factor medication include IIb/IIIa inhibitor , anticoagulant , type procedure , obesity smoking status , etc . Lower level platelet surface expression α2β1 integrin associate increase risk bleed complication follow hybrid procedure , especially low level integrin expression associate risk factor may exacerbate bleed vigorous anti-coagulation , aggressive anti-platelet therapy genetic risk factor contribute hemorrhagic phenotype . Conversely , high level expression α2β1 integrin likely associate great tendency thrombotic complication modify coexist risk factor .</detailed_description>
	<criteria>Patients recruit study undergo elective hybrid procedure [ percutaneous coronary intervention ( PCI ) follow minimally invasive coronary artery bypass graft ( CABG ) surgery valve surgery ] . Both male female enrol study . The age population 1870 year old . No one ethnic group gender target exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Genetic Polymorphism</keyword>
	<keyword>Integrin alpha2beta1</keyword>
	<keyword>Phenotype</keyword>
</DOC>